PASADENA, California, October 19, 2021 / PRNewswire / – Today, Pacific Research Institute posted a issue file revealing overwhelming public disapproval of the Medicare reforms Congress is considering as part of its $ 3.5 trillion expense bill.
Click here to read the full brief, “Drug Pricing Proposals Threaten America’s Most Vulnerable Patients.”
“It is a relief that Americans are opposing Congressional drug pricing proposals once voters learn the real consequences of these misguided reforms,” ââsaid Sally C. Pipes, dissertation co-author and PRI chairman, CEO, and Thomas W. Smith Fellow in Health Care Policy.
To reduce Medicare costs, lawmakers want U.S. officials to negotiate prices with drug makers. In reality, these “negotiations” amount to the imposition of a price control system. The proposals include linking drug prices to those paid by the Veterans Health Administration or by health systems in Canada and Europe. In either case, bureaucrats place a value on a person’s life based on their age and health, then undertake a cost-benefit analysis to determine whether to cover a drug and how much to pay for it. – and who is and is not eligible for certain drugs.
âAmerica’s most vulnerable patients could lose hundreds of new life-saving drugs,â Pipes said.
Although leaders have assured their members that these policies are popular with voters, a new poll and focus group data from OnMessage Inc. reveals that when Americans learn how the government would set prices, support drops dramatically. .
According to a investigation likely voters in general elections:
- When asked if Medicare should base its drug prices on decisions made by Canada and Europe, nearly 60% oppose it.
- Almost 78% of voters oppose the government setting drug prices on the basis of calculations that determine the value of a patient’s life (so-called QALY-based systems).
- When told that under plans such as those being considered by the House and Senate, “the elderly or disabled are less likely to get the latest drugs,” more than 72% of voters said that they were less likely to support reform.
- When asked if they would be more or less likely to support a congressional candidate who voted for one of these drug price reforms, nearly 66% said “less likely”, and more half said “much less likely”.
Focus groups swing voters expressed strong disapproval of these policies. One described the policies that rely on QALY as “government playing god”.
Another said: “It is unnecessary evil for someone to make these decisions outside of the doctor.”
âThese results are expected to fundamentally transform the way Washington drug pricing reform is approaching, âPipes said. âOur politicians must put the best interests of patients first. “
About the Pacific Research Institute
202-471-4228 ext. 130
View original content to download multimedia:https://www.prnewswire.com/news-releases/new-brief-focus-groups-overwhelming-disapprove-of-government-negotiated-drug-pricing-301402962.html
SOURCE Pacific Research Institute